Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Clinical Trial
Official title:
Stimulating Immune Response With Neoadjuvant Human Papilloma Virus (HPV)-16 Specific Vaccination in HPV-Oropharyngeal Squamous Cell Carcinoma (HPV-OPSCC)
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes (locally advanced). PDS0101 is a vaccine made from specific peptides that may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving PDS0101 with or without pembrolizumab may kill more tumor cells in patients with locally advanced human papillomavirus-associated oropharynx cancer before surgery so that it may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.
PRIMARY OBJECTIVE: I. To determine pathologic and human papillomavirus cell-free tumor deoxyribonucleic acid (ctHPVDNA) response to liposomal HPV-16 E6/E7 multipeptide vaccine PDS0101 (PDS0101) or PDS0101 plus pembrolizumab in patients with high risk human papillomavirus-associated oropharynx cancer (HPV-OPSCC). SECONDARY OBJECTIVES: I. To determine tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. II. To determine progression-free survival and overall survival. TERTIARY OBJECTIVES: I. To determine the safety of PDS0101 delivered alone or with pembrolizumab. CORRELATIVE RESEARCH OBJECTIVES: I. Determine the changes in tumor microenvironment (TME) with PDS0101 alone or with pembrolizumab. II. Determine circulating ctHPVDNA as a biomarker for tumor response. III. Determine HPV16-specific T-cell response utilizing multiplex flow cytometry and other parameters. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive PDS0101 subcutaneously (SC) on day 1 of each cycle. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or fludeoxyglucose F-18 (FDG)-positron emission tomography (PET)/CT and blood sample collection throughout the trial. Patients may undergo a biopsy during screening and on the trial. ARM B: Patients receive PDS0101 SC on day 1 and pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or FDG-PET/CT and blood sample collection throughout the trial. Patients may undergo a biopsy during screening and on the trial. After completion of study treatment, patients are followed every 3 months for up to 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05172245 -
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
|
Phase 1 | |
| Withdrawn |
NCT04140513 -
Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer
|
N/A | |
| Completed |
NCT04489212 -
Study of Mucosal Sparing Adjuvant Radiotherapy After Surgical Exploration in HPV+ Head and Neck Cancer of Unknown Primaries
|
N/A | |
| Terminated |
NCT03618134 -
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
|
Phase 1/Phase 2 | |
| Suspended |
NCT04162873 -
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
|
Phase 2 | |
| Recruiting |
NCT06356272 -
Oropharynx (OPX) Biomarker Trial
|
||
| Active, not recruiting |
NCT04576091 -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
|
Phase 1 | |
| Recruiting |
NCT04900623 -
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
|
Phase 2 | |
| Active, not recruiting |
NCT04920344 -
Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy
|
Phase 2 | |
| Terminated |
NCT04106362 -
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05541016 -
Blood-Based Biomarkers to Inform Treatment and Radiation Therapy Decisions for HPV Associated Oropharyngeal Squamous Cell Head and Neck Cancers
|
Phase 2 | |
| Recruiting |
NCT05136196 -
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
|
Phase 2 | |
| Recruiting |
NCT03010150 -
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
|
||
| Recruiting |
NCT04533750 -
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
|
Phase 1 | |
| Recruiting |
NCT03811015 -
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03258554 -
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
|
Phase 2/Phase 3 |